{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytochrome+P-450",
    "query": {
      "condition": "Cytochrome P-450"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 121,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytochrome+P-450&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T21:26:30.952Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01980329",
      "title": "Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytochrome P450 CYP3A5 Enzyme Polymorphism",
        "Healthy Subjects",
        "Pharmacokinetics of Maraviroc"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2013-01",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-06",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01980329"
    },
    {
      "nct_id": "NCT01273168",
      "title": "Endoxifen in Adults With Hormone Receptor Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hormone Receptor-Positive Breast",
        "Gynecologic",
        "Desmoid",
        "Hormone Receptor-Positive Neoplasms"
      ],
      "interventions": [
        {
          "name": "Z-Endoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-03-01",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273168"
    },
    {
      "nct_id": "NCT03950960",
      "title": "A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "BMS-986256",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2019-05-02",
      "completion_date": "2019-08-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03950960"
    },
    {
      "nct_id": "NCT01784536",
      "title": "Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Single-Dose IV Oritavancin Diphosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 16,
      "start_date": "2013-01",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01784536"
    },
    {
      "nct_id": "NCT01330589",
      "title": "Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "St. Johns Wort",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lancaster General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-04",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2017-10-05",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Lancaster, Pennsylvania",
      "locations": [
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01330589"
    },
    {
      "nct_id": "NCT00362726",
      "title": "Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone maleate",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir Sulphate",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir Sulphate + Rosiglitazone maleate",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir Sulphate + Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2006-09",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2011-04-08",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Hamilton, New Jersey",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362726"
    },
    {
      "nct_id": "NCT02428660",
      "title": "Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytochrome P450 CYP2D6 Enzyme Deficiency",
        "Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant",
        "Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant",
        "Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant",
        "Cytochrome P450 CYP2C9 Enzyme Deficiency",
        "Cytochrome P450 CYP2C19 Enzyme Deficiency",
        "Drug Metabolism, Poor, CYP2D6-RELATED",
        "Drug Metabolism, Poor, CYP2C19-RELATED",
        "CYP2D6 Polymorphism"
      ],
      "interventions": [
        {
          "name": "Pharmacogenetic testing",
          "type": "GENETIC"
        },
        {
          "name": "Software-based drug & gene interaction risk analysis",
          "type": "OTHER"
        },
        {
          "name": "MTM",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Genelex Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 341,
      "start_date": "2015-02",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02428660"
    },
    {
      "nct_id": "NCT03258372",
      "title": "Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Mifepristone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2017-08-16",
      "completion_date": "2017-11-29",
      "has_results": false,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03258372"
    },
    {
      "nct_id": "NCT04201197",
      "title": "Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-Interactions"
      ],
      "interventions": [
        {
          "name": "Inje cocktail",
          "type": "DRUG"
        },
        {
          "name": "THC Cannabis extract",
          "type": "DRUG"
        },
        {
          "name": "THC/CBD Cannabis Extract",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 22,
      "start_date": "2020-11-10",
      "completion_date": "2022-07-28",
      "has_results": true,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201197"
    },
    {
      "nct_id": "NCT03173170",
      "title": "A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "TAK-954",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-31",
      "completion_date": "2017-07-24",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-06-25T21:26:30.952Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173170"
    }
  ]
}